Cargando…
A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review
For advanced non-small cell lung cancer (NSCLC) patients with common epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or the exon 21 L858R mutation), tyrosine kinase inhibitors (TKIs) are the standard therapies. However, EGFR germline mutations are extremely rare in lung cancer,...
Autores principales: | Li, Dan, Liu, Xin, Cui, SaiQiong, Yang, DaFu, Zhu, Yue, Pan, Evenki, Yang, Peng, Dai, ZhaoXia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868143/ https://www.ncbi.nlm.nih.gov/pubmed/36698436 http://dx.doi.org/10.2147/OTT.S391766 |
Ejemplares similares
-
NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma
por: Li, Dan, et al.
Publicado: (2021) -
Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
por: Yang, Dafu, et al.
Publicado: (2021) -
The broad spectrum of tyrosine kinase inhibitors. Treatment of a rare EGFR R776H mutation with Osimertinib: Case report
por: Cui, Joyce, et al.
Publicado: (2023) -
Case Report: Lung adenocarcinoma associated with germline ERCC2 frameshift mutation
por: Liu, Lili, et al.
Publicado: (2023) -
Efficacy of afatinib in a patient with rare EGFR (G724S/R776H) mutations and amplification in lung adenocarcinoma: A case report
por: He, Shu-Yan, et al.
Publicado: (2021)